US 11,850,334 B2
Immobilised biological entities
Dagmar Pikas, Upplands Vasby (SE); Johan Riesenfeld, Upplands Vasby (SE); Karin Leontein, Upplands Vasby (SE); Eva Koch, Upplands Vasby (SE); and Stefan Oscarson, Belfield (IE)
Assigned to Carmeda AB, Upplands Väsby (SE)
Appl. No. 17/282,691
Filed by CARMEDA AB, Upplands Väsby (SE)
PCT Filed Oct. 3, 2019, PCT No. PCT/EP2019/076842
§ 371(c)(1), (2) Date Apr. 2, 2021,
PCT Pub. No. WO2020/070258, PCT Pub. Date Apr. 9, 2020.
Claims priority of application No. 18198421 (EP), filed on Oct. 3, 2018.
Prior Publication US 2021/0379253 A1, Dec. 9, 2021
Int. Cl. A61L 33/00 (2006.01); A61L 33/06 (2006.01); C08L 5/10 (2006.01)
CPC A61L 33/0023 (2013.01) [A61L 33/062 (2013.01); C08L 5/10 (2013.01); A61L 2300/236 (2013.01); A61L 2300/42 (2013.01)] 32 Claims
 
1. An anticoagulant surface which surface has covalently bound thereto a plurality of fragments of heparin, wherein said fragments consist of 5-18 saccharide units and at least some of said plurality of fragments comprise polysaccharide sequence A:

OG Complex Work Unit Chemistry
wherein R=Ac or SO3−
which surf ace catalyses the inhibition of FIIa and FXa by AT, and wherein the surface has a heparin fragment concentration of at least 1 μg/cm2.